Cue Biopharma (FRA:1UC) Net Income From Continuing Operations : €-37.66 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cue Biopharma's net income from continuing operations for the three months ended in Mar. 2025 was €-11.34 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was €-37.66 Mil.

Cue Biopharma Net Income From Continuing Operations Historical Data

The historical data trend for Cue Biopharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Net Income From Continuing Operations Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-36.81

-39.08

-50.04

-46.52

-38.84

Cue Biopharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															-11.36	-9.45	-7.80	-9.07	-11.34

Cue Biopharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-37.66 Mil.

Cue Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (FRA:1UC) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

CUE:USA 1UC:Germany

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Cue Biopharma Headlines

No Headlines